Adachi, Y., Yoshida, J., Kodera, Y., Kiss, T., Jakusch, T., Enyedy, E.A., Yoshikawa, Y. and Sakurai, H. (2006) Oral Administration of a Zinc Complex Improves Type 2 Diabetes and Metabolic Syndromes. Biochemical and Biophysical Research Communications, 351, 165-170.
http://dx.doi.org/10.1016/j.bbrc.2006.10.014

has been cited by the following article:

• TITLE: α-Glucosidase Inhibition by New Schiff Base Complexes of Zn(II)

  AUTHORS: Rie Miyazaki, Hiroyuki Yasui, Yutaka Yoshikawa

  KEYWORDS: α-Glucosidase Inhibitory Effect, Zn(II) Complexes, Schiff Bases, Diabetes Mellitus

  JOURNAL NAME: Open Journal of Inorganic Chemistry, Vol.6 No.2, April 12, 2016

  ABSTRACT: There are many reports that divalent alkaline earth, first-row transition metals, and Zn(II) ions have α-glucosidase inhibitory effects. Cu(II) and Zn(II) ions, in particular, have strong α-glucosidase inhibitory effects. Several Schiff bases also display α-glucosidase inhibitory effects. In this study, we focused on safe and highly effective complexes including Zn(II) ion. We prepared and characterized the Zn(II) complexes with four different Schiff bases (N-salicylidene-β-alanine (N-sβ), N-N’-bis (salicylidene) ethylenediamine (N-bsE), N, N’-bis (salicylidene)-phenylenediamine (N-bsP), and 1-[(2-dimethylaminoethylimino) methyl]naphtholate (DMN)) and investigated their α-glucosidase inhibitory effects in vitro, using α-glycosidases from Saccharomyces sp. and rat small intestine, and in vivo, using a sucrose tolerance test. The Zn(II) complexes with DMN showed the highest in vitro and in vivo α-glucosidase inhibitory effects in this study.